Recent News

Click here to join our mailing list for the latest news and updates

November 22, 2011

MABCURE RECEIVES $500,000 LICENSING FEE AS WELL AS 12.5% ONGOING ROYALTY FOR ITS PROSTATE CANCER DIAGNOSTIC TECHNOLOGY

» MORE

March 8, 2011

MABCURE STUDY RESULTS ON A NEW OVARIAN CANCER DIAGNOSTIC BLOOD TEST BEING PRESENTED AT THE ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGICAL ONCOLOGISTS

» MORE

March 1, 2011

MABCURE INC - CORPORATE UPDATE

» MORE

January 20, 2011

MABCURE SECURES $10 MILLION FUNDING COMMITMENT FROM AN INSTITUTIONAL INVESTOR MANAGED BY ROSWELL CAPITAL PARTNERS

» MORE

MabCure, Inc.


MabCure is a biotechnology company whose vision is to change the perception of cancer as a largely incurable disease. MabCure's primary mission is to develop novel diagnostics for the early detection of cancer when the disease is still localized and treatable, and where the chances for cure are greater than 90 percent.

MabCure’s longer term goals are to provide physicians with novel antibodies and drugs that effectively attack only cancer cells while sparing normal tissue and minimize toxic side effects.

[Video] See President & CEO, Dr. Amnon Gonenne, talk about MabCure and its technology.